Patents by Inventor Gwen Nichols

Gwen Nichols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11382892
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 12, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20220031726
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 3, 2022
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20210069149
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: Kellie Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20200253999
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 13, 2020
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20200085788
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 19, 2020
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20190328708
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Patent number: 9956243
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example: and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 1, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20170227544
    Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain MDM2 protein expressing cells and, optionally additional co-variates selected from a gene signature as disclosed herein, p53 mutation status, the patient's age and ECOG score at baseline as a biomarker for predicting said patient's response to treatment.
    Type: Application
    Filed: October 7, 2015
    Publication date: August 10, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Steven D. Blotner, Gong Chen, Lori Jukofsky, Gwen Nichols, William E. Pierceall, Bernhard Reis, Ruediger Rueger, Hua Zhong
  • Patent number: 9657351
    Abstract: Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 23, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Hua Zhong, David Geho, Gong Chen, Gwen Nichols, Markus Dangl
  • Patent number: 9486445
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 8, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • Publication number: 20160303158
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 20, 2016
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20160129034
    Abstract: The present application discloses pharmaceutical products comprising a) as a first component a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of the compound of formula (A) or a pharmaceutically acceptable salt, ester or prodrug of said compound; b) a second component comprising a pharmaceutical composition comprising a therapeutically effective amount of capecitabine; and c) a third component comprising a pharmaceutical composition comprising a therapeutically effective amount of oxaliplatin. The application also discloses methods for the treatment of cancer using said products, as well as kits containing said products.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 12, 2016
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20160129033
    Abstract: There are provided pharmaceutical products comprising a) a first component comprising the compound of formula (A); and b) a second component comprising capecitabine for the simultaneous or sequential treatment of cancer, kits comprising said product as well as methods for treating cancer patients by administering said product.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 12, 2016
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20160051525
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Application
    Filed: July 22, 2015
    Publication date: February 25, 2016
    Inventors: Brian HIGGINS, Kenneth KOLINSKY, Gwen NICHOLS, Kathryn PACKMAN, Fei SU
  • Patent number: 9216170
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 22, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • Publication number: 20150211073
    Abstract: Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.
    Type: Application
    Filed: December 4, 2014
    Publication date: July 30, 2015
    Inventors: Hua Zhong, David Geho, Gong Chen, Gwen Nichols, Markus Dangl
  • Publication number: 20150202182
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 23, 2015
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20150157603
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 11, 2015
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20150126575
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20140200255
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Inventors: BRIAN HIGGINS, GWEN NICHOLS, LIN-CHI CHEN